Ashish Parikh, MD
Cardiovascular Disease · Newark, DENPI 1649247487
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (48.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Angiodynamics, Inc. at 48.1% of the total. Reporting peaked in 2023 at $13,273 and has fallen 94.4% since, to $745 in 2025. Among cardiovascular disease clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $192.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$13K
- Johnson & Johnson$11K
- Abbott$630
- Pfizer$380
- Merck$302
- Boehringer Ingelheim$219
- plus $1K from 21 others
Across 1 payment — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$3K
What the payments were for
- Speaking & faculty fees$10,50040%
- Food & beverage$3,04012%
- Education$1591%
- Other$12,66748%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $12,688 |
| Johnson & Johnson | 12 | $10,741 |
| Abbott | 18 | $630 |
| Pfizer | 27 | $380 |
| Merck | 14 | $302 |
| Boehringer Ingelheim | 7 | $219 |
| Novo Nordisk | 8 | $208 |
| AstraZeneca | 5 | $154 |
| Boston Scientific | 3 | $130 |
| Lemaitre Vascular, Inc. | 1 | $94 |
| Lexicon Pharmaceuticals, Inc. | 4 | $81 |
| Cardiovascular Systems Inc. | 3 | $81 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $79 |
| Novartis | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Bayer | 3 | $63 |
| Esperion Therapeutics, Inc. | 3 | $58 |
| Digirad Health, Inc | 1 | $54 |
| Janssen Scientific Affairs, LLC | 1 | $53 |
| Philips North America LLC | 2 | $46 |
| Terumo Medical Corporation | 1 | $42 |
| Heartflow, Inc. | 1 | $26 |
| Medtronic(2 entities) | 2 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $16 |
| Acarix USA Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$12,667
- XARELTO$10,625
- ENSITE$147
- JARDIANCE$119
How this compares
$26,366 in reported general payments places this provider in the 90th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 269 | $319,343 |
| EliquisApixaban | 189 | $183,522 |
| EntrestoSacubitril/Valsartan | 66 | $66,524 |
| JardianceEmpagliflozin | 26 | $27,350 |
| VascepaIcosapent Ethyl | 12 | $11,000 |
| FarxigaDapagliflozin Propanediol | 15 | $10,528 |
| Metoprolol Succinate | 647 | $10,403 |
| Atorvastatin Calcium | 651 | $8,557 |
| Ranolazine ErRanolazine | 55 | $6,298 |
| Rosuvastatin Calcium | 214 | $4,405 |
| ClopidogrelClopidogrel Bisulfate | 265 | $3,568 |
| Losartan Potassium | 279 | $3,382 |
| Amlodipine Besylate | 407 | $3,171 |
| Hydralazine Hcl | 172 | $2,746 |
| Ezetimibe | 63 | $2,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $10,741 | $319,343269 claims |
| PfizerEliquis | $380 | $183,522189 claims |
| NovartisEntresto | $77 | $66,52466 claims |
| Boehringer IngelheimJardiance | $219 | $27,35026 claims |
| AstraZenecaFarxiga | $154 | $10,52815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
- Francis PalermoNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.